CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

  • Posted by: BIOCON

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

  • Posted by: BIOCON

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States

  • Posted by: BIOCON

Biocon Academy Conducts its 9th Graduation Day

  • Posted by: BIOCON

Biocon Foundation Marks 20 Years of Transforming Lives Through Impactful Social Initiatives

  • Posted by: BIOCON

Biocon Limited launches its Glucagon-like peptide-1 (GLP -1), Liraglutide, in the United Kingdom

  • Posted by: BIOCON

Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States

  • Posted by: BIOCON

Biocon Foundation Dedicates Metro Pillars Public Art Project to ‘Everyday Champions’ of Bengaluru

  • Posted by: BIOCON

Equillium Inc. and Biocon Limited Announce Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

  • Posted by: BIOCON

Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>